What is going on with the price of the Epipen?
Mylan CEO, Heather Bresch, spoke on CNBC Thursday morning to discuss the frenzy surrounding price hikes. Bresch claims that “the system” is to blame for the skyrocketing price of EpiPens:
Families weren’t hearing it (see Twitter comments below).
Breach solution? She said Mylan would double eligibility for patient assistance to EpiPen users, eliminating immediate out-of-pocket costs for the uninsured and under-insured.
It also said patients would be able to use a savings card to cover up to $300 of cost of the two-pack of EpiPens.
A family of four with an annual income of up to $97,200 would pay nothing out of pocket for an injector, the company said. It also blamed insurance companies for requiring patients to pay an increasing share of the costs for medications.
Mylan said it had distributed more than 700,000 EpiPens to 65,000 schools in the United States.